14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the...read more
CoLucid Pharmaceuticals, a late-stage biotech developing therapies for acute migraines, lowered the proposed deal size and valuation for its upcoming IPO on Tuesday. The Burlington, MA-based company now plans to raise $55 million by offering 5.5 million...read more
This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, last week's mediocre returns suggest that upcoming IPOs could face valuation pushback while some struggle to...read more
US IPO Weekly Recap: With 8 IPOs it's Bo-Time for Bojangles and no time for biotechs
14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the...read more
CoLucid Pharmaceuticals prices IPO at $10, below originally proposed range
below its original $13 to $15 range. The company increased the shares offered, dropped the IPO price to $10 and...read more
A smaller migraine: CoLucid Pharmaceuticals slashes proposed valuation by 28% ahead of IPO
CoLucid Pharmaceuticals, a late-stage biotech developing therapies for acute migraines, lowered the proposed deal size and valuation for its upcoming IPO on Tuesday. The Burlington, MA-based company now plans to raise $55 million by offering 5.5 million...read more
Week ahead: 14 IPOs planned for the week of May 4
This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, last week's mediocre returns suggest that upcoming IPOs could face valuation pushback while some struggle to...read more